[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-impairment-mci-amnestic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-impairment-mci-amnestic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100633617","acoustic-stimulation-during-sleep-effects-on-memory-and-p-tau217-in-mci-100633617",false,"NCT07529015","Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI","The Impact of Phase-locked Acoustic Stimulation on Sleep Structure, Memory Consolidation, and Plasma p-tau217 in Patients With Mild Cognitive Impairment","PAS-MCI","Inclusion Criteria:\n\n* Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and positive state of plasma p-tau217.\n* Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and negative state of plasma p-tau217 for aMCI negative group.\n* Cognitively unimpaired older subjects aged ≥ 65 years, Mini-mental state examination ≥28, and negative for plasma p-tau217.\n\nExclusion Criteria:\n\n* Diagnosis of dementia due to AD or any other type of dementia.\n* Presence of any diagnosed sleep disorder such as narcolepsy, severe insomnia, severe obstructive sleep apnea, or severe chronic lack of sleep.\n* Hearing problems.\n* Analphabet individuals.\n* Comorbidities such as cancer, severe depression, severe renal or hepatic insufficiency, history of seizures, and severe cardiac or respiratory failure.\n* Alcohol and substance abuse.\n* Magnetic resonance imaging (MRI) evidence of stroke, hydrocephalus, a space-occupying lesion, or any clinically relevant central nervous system disease.\n* Existence of untreated (or treated for less than 3 months prior to the screening visit) vitamin B12 or folate deficiency.\n* Presence of untreated thyroid disease.\n* Use of betablockers, antidepressants, neuroleptics, and hypnotics, within 15 days before conducting polysomnography.",true,"ALL","60 Years",{"count":21,"type":22},114,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether acoustic stimulation during sleep can enhance slow-wave sleep (SWS), improve cognitive function, and reduce AD-related pathology in individuals with mild cognitive impairment (MCI), compared with cognitively healthy participants.\n\nThe main questions it aims to answer are:\n\n1. Does acoustic stimulation increase SWS (e.g., slow oscillation and sleep spindle activity) in individuals with MCI?\n2. Does enhancing SWS lead to improvements in memory and cognitive performance?\n3. Does acoustic stimulation influence plasma p-tau217 levels as a marker of underlying Alzheimer's disease pathology? Researchers will compare participants receiving acoustic stimulation during sleep with those not receiving stimulation to evaluate its effects on sleep architecture, cognition, and plasma biomarkers.\n\nParticipants will:\n\n* Undergo sleep recordings to assess sleep architecture, including SWS, slow oscillations, and sleep spindles\n* Receive acoustic stimulation during sleep across multiple nights\n* Complete cognitive assessments, particularly memory-related tasks\n* Provide blood samples to measure plasma p-tau217 levels\n* Provide clinical and demographic information for analysis",[28,29,30],"Alzheimer's Disease (AD)","Mild Cognitive Impairment (MCI) Amnestic","Cognitively Unimpaired",[32,33,34,35,36,37,38,39,40,41],"Alzheimer's disease","acoustic stimulation","declarative memory","amnestic mild cognitive impairment","sleep spindle","episodic memory","sleep EEG","slow-wave sleep","p-tau217","slow oscillation","NOT_YET_RECRUITING","2026-04-07",{"date":45,"type":46},"2026-04-14","ACTUAL",{"date":48,"type":22},"2026-04",{"date":50,"type":22},"2028-12",{"name":52,"class":53},"Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":87,"locationsCount":54},"100627475","effect-of-striatal-temporal-interference-stimulation-on-language-processing-in-neurodegenerative-diseases-100627475","NCT07449117","Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases","Immediate Effects of Non-invasive Temporal Interference Stimulation Targeting Deep Fronto-Striatal Structures on Language Processing and Behavioral Performance in Patients With Neurodegenerative Diseases","Inclusion Criteria:\n\n* Possible or probable Mild Cognitive Impairment with Lewy Bodies (MCI-LB), in Parkinson's Disease (MCI-PD) or Amnestic Mild Cognitive Impairment (aMCI).\n\nExclusion Criteria:\n\n* Any severe psychiatric disorder.\n* History of other neurological diseases affecting the central nervous system.\n* Severe head trauma.\n* Uncompensated internal or oncological disease.\n* Presence of MRI-incompatible metal in the body (e.g., pacemaker).","80 Years",{"count":64,"type":22},70,[25],"The purpose of this study is to investigate the immediate effects of non-invasive temporal interference stimulation (TIS) targeting the striatum on sentence processing and brain connectivity in patients with neurodegenerative diseases.",[29,68,69],"Lewy Body Disease With Mild Cognitive Impairment","Parkinson's Disease With Mild Cognitive Impairment",[71,72,73,74,75,76,77,78,79],"Temporal Interference Stimulation","Functional Magnetic Resonance Imaging","Sentence Comprehension","Language Processing","Brain Connectivity","Striatum","Fronto-striatal Circuit","Mild Cognitive Impairment","Neurodegenerative Diseases","RECRUITING","2026-02-27",{"date":83,"type":46},"2026-03-04",{"date":85,"type":22},"2026-03",{"date":50,"type":22},{"name":88,"class":53},"Masaryk University",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100599330","early-stage-of-alzheimers-and-parkinsons-diseases-hearing-relevance-saphir-100599330","NCT07083089","Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)","Phenotyping of Audition in Patients With Early Stage of Neurodegenerative Disorders (Alzheimer and Parkinson' Diseases)","SAPHIR","Inclusion Criteria: All subjects\n\n1. Man or woman aged between 50 and 85 years old at baseline.\n2. Fluent in French (native language)\n3. Be considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator (understanding of the information included in the protocol, and requests to realize the investigations, good general health and able to move around).\n4. Affiliated to Public Health Insurance (Sécurité Sociale)\n5. Signed and dated informed consent form.\n\nFor amnestic MCI:\n\nDiagnosis of amnestic MCI, according to international diagnosis criteria (NIA-AA, 2011) with MoCA≥23 or MMSE\\>24.Patients must exhibit predominantly cognitive impairments in episodic memory, defined by a score on the RL\u002FRI 16-item test with a free recall score of less than 18\u002F48 and a total recall score of less than 40\u002F48.\n\nFor Parkinson Patients:\n\nEstablished clinical diagnosis of Parkinson's disease according to Postuma et al. 2015 with bradykinesia associated with resting tremor or rigidity, no exclusion criteria or red flag with MOCA ≥23.\n\nFor controls:\n\nNo diagnosis of neurological disease such as Parkinson's disease or MCI associated or not with Alzheimer's disease Displays normal cognitive status with a MoCA score ≥ 26.\n\nNon-inclusion criteria:\n\n1. Known hearing pathologies leading to conductive hearing loss (otosclerosis, a diagnosed pathology of the ear canal, tympanic membrane, ossicles or 3rd window), otitis, congenital deafness or sensorineural hearing loss associated to Menière's disease.\n2. Psychiatric diseases other than neurodegenerative etiology\n3. Neurological or neurovascular disorders (Stroke, epilepsy, dementia)\n4. Motor complications that could interfere with audiological assessment\n5. Known Diagnosis of type 2 diabetes\n6. Alcohol or drug addiction\n7. Cochlear implant\n8. Known ototoxic drug therapy:\n\n   1. Antibiotics: Aminosides IV, macrolides, tetracyclines in the last 15 days prior to inclusion\n   2. Antipaludic drugs: quinine, hydroxychloroquine, chloroquine in the last 15 days prior to inclusion\n   3. Platinum-based chemotherapy at any time prior to inclusion.\n   4. Loop diuretics: furosemide (max oral dose of ≤60mg\u002Fday) at inclusion and during the study.\n   5. Salicylate derivatives at high dose (Kardegic allowed at dose ≤320mg\u002Fday) at inclusion and during the study.\n9. History of otological surgical act.\n10. On-going pregnancy or breast-feeding.\n11. Adults protected by law: in vulnerable social situations or unable to express consent.\n12. Under another protocol that may interfere with the analysis of the results.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if one or more of the following criteria are applicable during visit 2:\n\n1. Abnormal otoscopy as defined by less than 90% of the tympanic membrane visible (cerumen ear plug, ear drum perforation, …)\n2. Conductive hearing loss defined by an air-bone threshold gap of 10 dB or greater based on the average of frequencies 0.5, 1, 2, and 4 kHz, and abnormal hearing thresholds (greater than 20 dB HL) for these frequencies.\n3. Abnormal tympanogram (other type than A)\n4. Asymmetric hearing loss: more than 15 dB difference in the pure-tone average (PTA) air conduction (for MCI patients and control group only)\n5. Single-sided deafness (SSD)\n6. Cophosis (PTAv \\> 120 dB)","50 Years","85 Years",{"count":100,"type":22},309,[25],"The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population. Specific focus is made on patients with speech-in-noise intelligibiltiy deficit despite normal tonal audiograms referred to as hidden hearing loss, with potential identification of associated biomarkers.",[29,104,105],"Parkinson Disease (PD)","Healthy Participants",[107,108,109,110],"hearing phenotype","audiometry","speech-in-noise intelligibility","electrophysiology","2025-12-08",{"date":113,"type":46},"2025-12-09",{"date":115,"type":46},"2025-03-24",{"date":117,"type":22},"2026-12",{"name":119,"class":120},"Cilcare SAS","INDUSTRY",4]